Compare with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PIRAMAL ENTERPRISES ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 22.4 -47.2 - View Chart
P/BV x 5.4 1.6 338.9% View Chart
Dividend Yield % 0.9 1.5 61.8%  

Financials

 ALKEM LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
PIRAMAL ENTERPRISES
Mar-19
ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,7203,303 82.4%   
Low Rs1,6601,797 92.4%   
Sales per share (Unadj.) Rs697.9716.5 97.4%  
Earnings per share (Unadj.) Rs96.179.7 120.6%  
Cash flow per share (Unadj.) Rs117.3107.9 108.7%  
Dividends per share (Unadj.) Rs25.0028.00 89.3%  
Dividend yield (eoy) %1.11.1 103.9%  
Book value per share (Unadj.) Rs515.21,477.5 34.9%  
Shares outstanding (eoy) m119.57184.45 64.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.13.6 88.2%   
Avg P/E ratio x22.832.0 71.2%  
P/CF ratio (eoy) x18.723.6 79.0%  
Price / Book Value ratio x4.31.7 246.3%  
Dividend payout %26.035.1 74.0%   
Avg Mkt Cap Rs m261,879470,292 55.7%   
No. of employees `00014.37.8 183.3%   
Total wages/salary Rs m15,05522,504 66.9%   
Avg. sales/employee Rs Th5,822.616,899.4 34.5%   
Avg. wages/employee Rs Th1,050.52,877.7 36.5%   
Avg. net profit/employee Rs Th802.01,879.9 42.7%   
INCOME DATA
Net Sales Rs m83,444132,153 63.1%  
Other income Rs m1,0423,128 33.3%   
Total revenues Rs m84,486135,281 62.5%   
Gross profit Rs m14,73466,290 22.2%  
Depreciation Rs m2,5285,202 48.6%   
Interest Rs m65144,097 1.5%   
Profit before tax Rs m12,59820,119 62.6%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1058,611 12.8%   
Profit after tax Rs m11,49314,701 78.2%  
Gross profit margin %17.750.2 35.2%  
Effective tax rate %8.842.8 20.5%   
Net profit margin %13.811.1 123.8%  
BALANCE SHEET DATA
Current assets Rs m54,960122,742 44.8%   
Current liabilities Rs m32,433310,810 10.4%   
Net working cap to sales %27.0-142.3 -19.0%  
Current ratio x1.70.4 429.1%  
Inventory Days Days8023 344.9%  
Debtors Days Days7239 185.8%  
Net fixed assets Rs m32,710116,904 28.0%   
Share capital Rs m239369 64.8%   
"Free" reserves Rs m61,368272,161 22.5%   
Net worth Rs m61,607272,530 22.6%   
Long term debt Rs m1,592270,196 0.6%   
Total assets Rs m99,433856,261 11.6%  
Interest coverage x20.41.5 1,398.4%   
Debt to equity ratio x01.0 2.6%  
Sales to assets ratio x0.80.2 543.7%   
Return on assets %12.26.9 177.9%  
Return on equity %18.75.4 345.8%  
Return on capital %21.012.4 168.8%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06115,200 105.7%   
Fx outflow Rs m2,4834,889 50.8%   
Net fx Rs m13,57810,312 131.7%   
CASH FLOW
From Operations Rs m5,851-115,975 -5.0%  
From Investments Rs m-7,414-8,265 89.7%  
From Financial Activity Rs m792107,525 0.7%  
Net Cashflow Rs m-731-16,650 4.4%  

Share Holding

Indian Promoters % 66.9 52.9 126.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.0 827.5%  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 16.5 -  
Shareholders   68,381 93,274 73.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SANOFI INDIA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  WYETH  TORRENT PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS